Condition
Renal Angiomyolipoma
Total Trials
5
Recruiting
1
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Active Not Recruiting2
Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05252585Phase 4Active Not RecruitingPrimary
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
NCT06453642Not ApplicableActive Not Recruiting
Evaluation of a Simple-Prep Controlled Embolic
NCT06683846Phase 2Recruiting
Ivonescimab in the Treatment of Multiple Advanced Tumors
NCT02654340Terminated
Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)
NCT03525834Phase 4CompletedPrimary
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
Showing all 5 trials